Evan Seigerman
Stock Analyst at BMO Capital
(0.16)
# 3,685
Out of 4,667 analysts
136
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $58.41 | +4.43% | 11 | Nov 12, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $94 → $102 | $89.61 | +13.83% | 14 | Nov 7, 2024 | |
| INCY Incyte | Reiterates: Underperform | $48 → $52 | $70.05 | -25.76% | 12 | Oct 30, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $128 → $114 | $124.35 | -8.32% | 14 | Oct 17, 2024 | |
| BIIB Biogen | Maintains: Outperform | $260 → $230 | $158.28 | +45.31% | 24 | Oct 17, 2024 | |
| LLY Eli Lilly | Maintains: Outperform | $1,001 → $1,101 | $749.72 | +46.85% | 8 | Aug 9, 2024 | |
| IRON Disc Medicine | Reiterates: Outperform | $50 → $70 | $63.46 | +10.31% | 5 | Jun 17, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $480 → $500 | $449.81 | +11.16% | 13 | May 31, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $30.94 | +29.30% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $11.00 | +263.64% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $748.23 | +5.32% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $2.68 | -6.54% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $289.72 | -16.12% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $4.15 | +189.31% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $25.01 | +139.90% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $27 | $1.72 | +1,469.77% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $3.21 | +834.58% | 3 | May 12, 2020 |
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $58.41
Upside: +4.43%
Gilead Sciences
Nov 7, 2024
Maintains: Outperform
Price Target: $94 → $102
Current: $89.61
Upside: +13.83%
Incyte
Oct 30, 2024
Reiterates: Underperform
Price Target: $48 → $52
Current: $70.05
Upside: -25.76%
Neurocrine Biosciences
Oct 17, 2024
Maintains: Market Perform
Price Target: $128 → $114
Current: $124.35
Upside: -8.32%
Biogen
Oct 17, 2024
Maintains: Outperform
Price Target: $260 → $230
Current: $158.28
Upside: +45.31%
Eli Lilly
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $749.72
Upside: +46.85%
Disc Medicine
Jun 17, 2024
Reiterates: Outperform
Price Target: $50 → $70
Current: $63.46
Upside: +10.31%
Vertex Pharmaceuticals
May 31, 2024
Maintains: Outperform
Price Target: $480 → $500
Current: $449.81
Upside: +11.16%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $30.94
Upside: +29.30%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $11.00
Upside: +263.64%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $748.23
Upside: +5.32%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $2.68
Upside: -6.54%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $289.72
Upside: -16.12%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $4.15
Upside: +189.31%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $25.01
Upside: +139.90%
Aug 13, 2021
Maintains: Outperform
Price Target: $30 → $27
Current: $1.72
Upside: +1,469.77%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $3.21
Upside: +834.58%